• GPI Home
  • Solutions
    • GPI pulse™
    • GPI Consulting
    • GPI Horizon Methodology
    • Case Studies
  • About Us
    • Our Team
    • Careers
  • Contact Us
  • Discover
    • Blog
    • Events
    • Resources
  • GPI Direct
medicine price
GPI forecasts price potential by correlating pricing and access data with real-world payer behavior
October 22, 2019 by Global Pricing Innovations (GPI)
Global Pricing Innovations (GPI) forecasts drug price potential using advanced analytics

  Today Global Pricing Innovations (GPI) reports that it has validated an analytical method for forecasting new drug price potential during early stage development, opening a pathway to digital transformation for teams engaged in pricing and market access. GPI has successfully forecasted prices…

October 1, 2019 by Global Pricing Innovations (GPI)
Pharma price and access pioneers, Global Pricing Innovations (GPI), continue growth with the strategic expansion to Cambridge, UK.

New office expansion enables GPI to accelerate growth in software engineering, professional services and customer support.   London, October 1st, 2019 Global Pricing Innovations (GPI), today announced the opening of its second UK office in Cambridge, UK which will help to strengthen the…

August 30, 2019 by Global Pricing Innovations (GPI)
Roche’s Tecentriq in combination with Abraxane approved for metastatic triple-negative breast cancer in Europe.

  Roche announced on Thursday, August 29, that Tecentriq (atezolizumab) in combination with Abraxane (protein-bound paclitaxel) had been approved in Europe for patients with PD-L1-positive, metastatic triple-negative breast cancer (TNBC). The Tecentriq combination marks the first cancer immunotherapy regimen to be available in…

August 23, 2019 by Global Pricing Innovations (GPI)
US Government is considering introduction of International Reference Pricing

President Trump’s administration has proposed to create an International Pricing Index (IPI) model for Medicare Plan B, which could bring international reference pricing (IRP) to the United States. The proposed change would apply to physician-administered therapies (covered by Medicare Part B) but not…

August 19, 2019 by Global Pricing Innovations (GPI)
Canada finalises new regulations to tackle high drug prices

  Earlier this month, the Government of Canada announced the final amendments to the Patented Medicines Regulations which estimates to save Canadians around $13 billion in the next decade and lay the foundation for National Pharmacare. The most significant reform to the regulations since…

June 19, 2019 by Global Pricing Innovations (GPI)
The new Pricing System in Russia will lead to price decreases for many medicines

  Amendments to the Pharmaceutical Law in Russia will take effect from June 2019 and will be completed by 1st January 2021. Medicines which are reimbursed in Russia are listed on the Essential Drugs List (EDL), in which there are currently 735 products,…

June 10, 2019 by Global Pricing Innovations (GPI)
Renting a lifetime therapy vs. Buying a ‘one-off’ – Has the high price tag historically hindered reimbursement?

  Only recently did FDA approve Zolgensma® (by AveXis, a Novartis company), a gene therapy costing 2.1$ million, making it the most expensive medicine in the history of pharma. Zolgensma®’s most compelling feature is that it is a ‘one-off’ treatment. It utilises a…

May 14, 2018 by Global Pricing Innovations (GPI)
Need a new approach to your pricing strategies? Watch GPI’s video to learn more about our innovative methodologies…
January 23, 2018 by Global Pricing Innovations (GPI)
What will shape the global pharmaceutical pricing environment in 2018?

One of the advantages of working in a global consultancy and technology solutions firm such as Global Pricing Innovations (GPI), which specializes in pharmaceutical pricing, is the wide exposure one receives to the many different challenges across disease areas, companies, and geographies. This…

Our partners
  • Privacy Policy
  • Terms of Use

| © Copyright 2018 Global Pricing Innovations. All Rights Reserved.

VAT registration: GB225169121